Skip to main content

Advertisement

SpringerLink
Log in

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

An Erratum to this article was published on 20 August 2008

Abstract

Malignant mesenchymal tumors consist of approximately 10% of uterine tumors. The majority of uterine sarcomas are leiomyosarcoma and endometrial stromal sarcoma (ESS). Surgery, radiotherapy, chemotherapy, and hormonal therapy are used for the treatment of ESS. Imatinib mesylate is indicated in the management of gastrointestinal stromal tumor and chronic myelogeneus leukemia. There is an interest to use imatinib mesylate in the treatment of c-kit positive ESS. We reported a case of 42-year-old female low-grade ESS progressed on chemotherapy and presented with objective response to imatinib mesylate. The treatment response was evaluated with FDG PET/CT. Complete metabolic response was detected. FDG PET, a sensitive method for tumor response evaluation on the basis of tumor metabolism changes, is useful for the evaluation of imatinib treatment in low-grade ESS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Moinfar F, Azodi M, Tavassoli FA (2007) Uterine sarcomas. Pathology 39:55–71

    Article  PubMed  Google Scholar 

  2. Hasiakos D, Papakonstantinou K, Kondi-Paphiti A, Fotiou S (2007) Low-grade endometrial stromal sarcoma of the endocervix. Report of a case and review of the literature. Eur J Gynaecol Oncol 28:483–486

    PubMed  CAS  Google Scholar 

  3. De Vita Jr VT, Hellman S, Rosenberg SA (2005) Cancer: principles and practice of oncology. In: Burke Tw, Mundt AJ, Muggia FM (eds) Cancers of the uterine body. 7th edn. Chap. 32.2. Philadelphia, USA, pp 1341–1360

  4. Sevinc A, Adli M, Kalender ME, Camci C (2007) Benign causes of increased serum CA-125 concentration. Lancet Oncol 8:1054–1055

    Article  PubMed  Google Scholar 

  5. Sevinc A, Camci C, Turk HM, Buyukberber S (2003) How to interpret serum CA-125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65:1–6

    Article  PubMed  Google Scholar 

  6. Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I (2003) The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecol Oncol 90:37–43

    Article  PubMed  Google Scholar 

  7. Lo KW, Yu MY, Cheung TH (2008) Low-grade endometrial stromal sarcoma with florid ıntravenous component. Gynecol Obstet Invest 66:8–11

    Article  PubMed  Google Scholar 

  8. Veroux P, Veroux M, Nicosia A, Bonanno MG, Tumminelli MG, Milone P, Petrillo G (2000) Thrombectomy of the inferior vena cava from recurrent low-grade endometrial stromal sarcoma: case report and review of the literature. J Surg Oncol 74:45–48

    Article  PubMed  CAS  Google Scholar 

  9. Ali RA, El-Hady el-SA, El-Zayat M (2008) Multilocular intrauterine cystic mass, atypical presentation of endometrial stromal sarcoma: a case report. Arch Gynecol Obstet 277:185–187

    Article  PubMed  Google Scholar 

  10. Wang KC, Liang DC, Su TH, Hung FY, Yang YC (1998) High-grade endometrial stromal sarcoma in a 10-year-old girl: case report. Changgeng Yi Xue Za Zhi 21:312–317

    PubMed  CAS  Google Scholar 

  11. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS (2007) Low grade endometrial stromal sarcoma: a single center’s experience with 22 cases. Int J Gynecol Cancer (in press)

  12. Ashraf-Ganjoei T, Behtash N, Shariat M, Mosavi A (2006) Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol 4:50

    Article  PubMed  Google Scholar 

  13. Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19:347–352

    Article  PubMed  CAS  Google Scholar 

  14. Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C (2006) A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol 101:545–547

    Article  PubMed  Google Scholar 

  15. Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M, Stroobants S, Mortelmans L, Schoffski P, Van Oosterom A (2006) Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 26:1247–1252

    PubMed  CAS  Google Scholar 

  16. Van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423

    Article  PubMed  Google Scholar 

  17. Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A (2005) Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 25:4591–4594

    PubMed  CAS  Google Scholar 

  18. Sevinc A, Camci C, Yilmaz M, Buyukhatipoglu H (2007) The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective. Onkologie 30:645–648

    Article  PubMed  Google Scholar 

  19. Zincirkeser S, Sevinc A, Kalender ME, Camci C (2007) Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging. World J Gastroenterol 13:2261–2262

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Medical Faculty, Gaziantep University, Gaziantep Oncology Hospital, 27310, Gaziantep, Turkey

    Mehmet Emin Kalender, Alper Sevinc, Mustafa Yilmaz, Coskun Ozsarac & Celalettin Camci

Authors
  1. Mehmet Emin Kalender
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alper Sevinc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mustafa Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Coskun Ozsarac
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Celalettin Camci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Emin Kalender.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00280-008-0819-2

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalender, M.E., Sevinc, A., Yilmaz, M. et al. Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol 63, 555–559 (2009). https://doi.org/10.1007/s00280-008-0786-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0786-7

Keywords

Search

Navigation